E.g., although the best-evidence synthesis judged the evidence indecisive due to inconsistent findings and small effects, the pooled estimate shows a worse 10-year absolute breast cancer-specific survival difference of 14.8% for BRCA2 carriers (Table 3, Fig. 3 and Fig. 4). Here, BRCA2 is linked to breast cancer.